IQVIA

<div class="infobox">
<div class="infobox-header">IQVIA Holdings</div>
<div class="infobox-content">
<table>
<tr><th>Ticker</th><td>IQV (NYSE)</td></tr>
<tr><th>Headquarters</th><td>Durham, North Carolina, USA</td></tr>
<tr><th>Founded</th><td>1982 (as IMS Health), merged 2016</td></tr>
<tr><th>Revenue</th><td>$7.4B (2024)</td></tr>
<tr><th>Employees</th><td>90,000+</td></tr>
<tr><th>Market Cap</th><td>~$38B</td></tr>
</table>
</div>
</div>

Overview

<div class="infobox">
<div class="infobox-header">IQVIA Holdings</div>
<div class="infobox-content">
<table>
<tr><th>Ticker</th><td>IQV (NYSE)</td></tr>
<tr><th>Headquarters</th><td>Durham, North Carolina, USA</td></tr>
<tr><th>Founded</th><td>1982 (as IMS Health), merged 2016</td></tr>
<tr><th>Revenue</th><td>$7.4B (2024)</td></tr>
<tr><th>Employees</th><td>90,000+</td></tr>
<tr><th>Market Cap</th><td>~$38B</td></tr>
</table>
</div>
</div>

Overview

IQVIA Holdings is a leading global provider of healthcare data, analytics, and real-world evidence solutions. The company was formed through the merger of IMS Health and Quintiles IMS in 2016, creating one of the world's largest healthcare intelligence platforms["@iqvia"]. With over four decades of experience in healthcare analytics, IQVIA serves pharmaceutical companies, biotechnology firms, medical device manufacturers, contract research organizations (CROs), and healthcare providers worldwide.

The company's significance to neurodegenerative disease research, particularly [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease), cannot be overstated. As the global burden of these conditions continues to grow—with an estimated 55 million people living with dementia worldwide and this number projected to rise to 139 million by 2050—IQVIA's real-world evidence capabilities have become essential for understanding disease progression, treatment patterns, and clinical outcomes["1"].

Historical Background

IMS Health Era (1982-2016)

IMS Health was founded in 1982 as Intercontinental Marketing Services, originally focusing on pharmaceutical sales tracking in the United States. Over the subsequent three decades, IMS evolved into the leading provider of healthcare market intelligence, collecting prescription data, sales figures, and promotional activity information from pharmacies, hospitals, and physicians worldwide. By 2015, IMS Health held data from over 45 billion healthcare transactions annually and served 90% of the world's top 50 pharmaceutical companies[@iqvia].

The company's evolution paralleled the growth of evidence-based medicine. In the 1990s, IMS expanded from basic sales tracking to include physician-level prescribing data, enabling pharmaceutical companies to understand prescribing patterns and optimize their marketing strategies. The early 2000s saw the development of electronic prescribing databases and the integration of medical claims data, providing a more complete picture of patient care.

Quintiles IMS Merger (2016)

The 2016 merger between IMS Health and Quintiles IMS created IQVIA, combining IMS's data collection capabilities with Quintiles' clinical trial expertise. This merger was transformative for the healthcare analytics industry, creating an end-to-end platform that could support drug development from early-phase research through post-market surveillance. The combined entity gained access to over 800 million patient records, enabling longitudinal analyses that were previously impossible[2].

Real-World Evidence Capabilities

Real-world evidence (RWE) has become increasingly critical in drug development, particularly for neurodegenerative diseases where clinical trials are complicated by long disease durations, heterogeneous patient populations, and the need for biomarkers that can track disease progression. IQVIA's RWE platform addresses these challenges through comprehensive data assets and sophisticated analytics capabilities[@iqviarwe].

Data Sources and Coverage

IQVIA maintains one of the world's largest repositories of healthcare data:

| Data Source | Coverage | Relevance to Neurodegeneration |
|-------------|----------|--------------------------------|
| EHR Data | 800M+ patient records | Longitudinal disease progression tracking |
| Prescription Data | 15B+ transactions annually | Treatment pattern analysis |
| Medical Claims | 150M+ patients annually | Healthcare utilization and costs |
| Specialty Databases | Oncology, rare disease, neurology | Disease-specific insights |
| Patient Registries | 200+ condition-specific | Natural history studies |
| Death Records | 45+ countries | Mortality analysis |

The EHR data infrastructure is particularly valuable for [Alzheimer's disease](/diseases/alzheimers-disease) research. Unlike randomized controlled trials that select for homogeneous patient populations, real-world EHR data captures the full spectrum of patients—including those with comorbidities, polypharmacy, and varying disease severities—that clinicians actually encounter[3]. This diversity is essential for understanding how treatments perform in heterogeneous real-world populations.

AD-Specific Capabilities

For Alzheimer's disease research, IQVIA provides[@iqvia_ads]:

Longitudinal Patient Journey Analysis

One of IQVIA's most valuable capabilities for AD research is the ability to track patient progression from mild cognitive impairment (MCI) to Alzheimer's disease over extended time periods. Using linked EHR and claims data, researchers can identify the sequence of diagnostic events, treatment initiation patterns, and healthcare utilization changes that characterize disease progression[4]. This longitudinal perspective is critical for:

• Identifying diagnostic pathways: Understanding how patients progress from initial cognitive complaints to definitive AD diagnosis
• Treatment timing analysis: Determining when patients receive disease-modifying therapies versus symptomatic treatments
• Care coordination: Mapping the healthcare team involved in AD patient management, including primary care physicians, neurologists, psychiatrists, and geriatricians
• Outcome measurement: Tracking progression through validated cognitive scales, functional assessments, and resource utilization

Cognitive Decline Modeling

IQVIA's analytics platform supports sophisticated modeling of cognitive decline using real-world data sources. By combining neuropsychological test results from EHR systems with clinical notes processed through natural language processing, the company can generate progression models that capture the heterogeneity of AD trajectories[5]. Key modeling capabilities include:

• Risk stratification models: Identifying patients at highest risk for rapid progression based on demographic, genetic, and clinical factors
• Treatment response prediction: Using machine learning to identify factors associated with differential response to cholinesterase inhibitors, memantine, and emerging disease-modifying therapies
• Subgroup identification: Discovering previously unrecognized patient subgroups with distinct progression patterns

Biomarker Validation

The validation of emerging biomarkers for AD diagnosis and progression monitoring represents a critical unmet need in the field. IQVIA's real-world datasets provide the scale and diversity necessary for robust biomarker validation studies[6]. The company has supported validation efforts for:

• Plasma biomarkers: Amyloid-beta and tau protein measurements from routine clinical lab data
• Neuroimaging findings: MRI and PET scan results extracted from radiology reports
• Genetic markers: APOE status and other genetic risk factors from integrated genomic databases
• Digital biomarkers: Movement patterns, speech characteristics, and other digital measurements from connected devices

Treatment Pattern Analysis

Understanding how AD and PD patients are treated in routine clinical practice is essential for drug development and health economics research. IQVIA's treatment pattern analyses have revealed important insights[7]:

• Time to treatment initiation: Average time from diagnosis to first prescription of AD-specific therapy
• Switching patterns: Rates and predictors of switching between cholinesterase inhibitors or adding adjunctive therapies
• Persistence and adherence: Real-world adherence rates and factors associated with treatment discontinuation
• Polypharmacy analysis: Prevalence and consequences of concomitant medication use in AD patients

Healthcare Resource Utilization

The economic burden of neurodegenerative diseases is substantial, with annual costs in the United States alone exceeding $300 billion for AD and $50 billion for PD. IQVIA's healthcare resource utilization data enables detailed analysis of[8]:

• Hospitalizations: Rates, predictors, and costs of hospital admissions in AD/PD patients
• Emergency department visits: Acute care utilization patterns
• Outpatient visits: Frequency and type of physician encounters
• Long-term care: Nursing home placement rates and associated costs
• caregiver burden: Indirect costs through family caregiver time and productivity loss

Clinical Trial Feasibility

IQVIA's patient-level data enables sophisticated clinical trial feasibility assessments that go beyond simple patient counting[9]. For AD and PD trials, this includes:

• Protocol feasibility: Simulating patient eligibility against real-world populations to predict enrollment rates
• Site selection: Identifying high-performing sites based on historical patient volumes and recruitment patterns
• Competitive trial analysis: Understanding the landscape of ongoing trials that may compete for the same patient populations
• Diversity analysis: Ensuring trial populations reflect the demographic diversity of the broader patient population

Clinical Trial Solutions

IQVIA's clinical trial capabilities span the entire drug development continuum, from early-phase proof-of-concept through late-phase registration trials and post-market commitment studies.

Trial Design and Execution

Protocol Feasibility

The traditional approach to protocol feasibility relies on investigator surveys and limited database queries. IQVIA's approach uses large-scale patient-level data to simulate eligibility criteria against actual patient populations[10]. This enables sponsors to:

• Quantify eligible population: Determine the exact number of patients meeting specific inclusion/exclusion criteria
• Identify enrollment barriers: Predict which protocol elements will limit enrollment based on real-world prevalence
• Optimize inclusion criteria: Suggest protocol modifications that preserve scientific validity while expanding eligible populations
• Timeline projection: Generate realistic enrollment timelines based on site-specific performance data

Site Selection and Feasibility

IQVIA's site selection platform integrates historical site performance data, patient population analytics, and competitive landscape information to identify optimal trial sites. For neurodegenerative disease trials, this includes:

• Neurology practice patterns: Understanding which physician specialties manage AD/PD patients in different geographic regions
• Academic vs community: Balancing the scientific capabilities of academic centers with the patient volume of community practices
• Patient access: Evaluating patient travel burdens and access to specialized diagnostic facilities
• Competitive density: Identifying regions with lower concentrations of competing trials

Patient Recruitment

Traditional patient recruitment relies on physician referrals, advertising, and site outreach. IQVIA's approach leverages EHR data to enable[11]:

• Direct patient identification: Using predictive models to identify patients who meet trial criteria but have not been enrolled
• Physician engagement: Providing site investigators with patient lists that meet their trial criteria
• Community outreach: Identifying patient advocacy groups, support organizations, and community centers for recruitment
• Digital recruitment: Enabling targeted digital advertising based on patient characteristics

Enrollment Analytics

Real-time enrollment analytics enable proactive trial management. IQVIA's platform provides:

• Enrollment dashboards: Visual displays of actual vs projected enrollment by site
• Risk identification: Early warning of enrollment shortfalls enabling intervention
• Root cause analysis: Understanding why certain sites underperform
• Adaptive design support: Data-driven recommendations for protocol amendments

Decentralized Trial Capabilities

The COVID- pandemic accelerated the adoption of decentralized trial designs, and IQVIA has developed comprehensive capabilities for hybrid and fully virtual trial execution[12].

Virtual Trial Platforms

IQVIA's virtual trial platform enables:

• Remote consent: Digital informed consent with verification and documentation
• Telehealth visits: Virtual investigator visits for safety assessments and efficacy evaluations
• ePRO collection: Electronic patient-reported outcomes through mobile devices
• Wearable integration: Continuous data collection from connected devices
• Direct-to-patient drug shipping: Investigational product delivery to patient homes

Remote Monitoring

Connected device integration enables home-based data collection that was previously only possible in academic medical centers[13]:

• Cognitive testing: Remote administration of validated cognitive assessments
• Motor assessments: Wearable-based measurement of movement characteristics in PD
• Vital signs: Continuous monitoring of blood pressure, heart rate, and other parameters
• Activity monitoring: Ambulatory activity tracking using accelerometers

ePRO Solutions

Electronic patient-reported outcomes have become essential for capturing patient-centric endpoints in neurodegenerative disease trials:

• Daily functioning: ADL and IADL assessments through smartphone applications
• Quality of life: Validated instruments like ADCS-ADL and QoL-AD
• Mood and behavioral symptoms: PHQ-9, NPI, and other psychiatric assessments
• Caregiver burden: Instruments measuring the impact on family caregivers

Analytics and Technology

AI and Machine Learning

IQVIA has invested heavily in artificial intelligence and machine learning capabilities to extract value from its vast data assets[14].

IQVIA AI Platform

The company's AI platform provides:

• Patient stratification: Machine learning models that segment patient populations based on clinical, demographic, and outcomes data
• Treatment effect heterogeneity: Identifying which patient subgroups benefit most from specific interventions
• Safety signal detection: Automated monitoring of adverse event patterns in real-world data
• Clinical decision support: Point-of-care recommendations based on evidence from large-scale data analysis

Natural Language Processing

Unstructured clinical text represents a vast source of untapped information. IQVIA's NLP capabilities enable[15]:

• Clinical note extraction: Identifying diagnoses, symptoms, medications, and procedures from free-text notes
• Radiology report analysis: Extracting findings from imaging reports
• Pathology report processing: Capturing histopathological diagnoses and findings
• Patient narrative analysis: Understanding patient experiences and quality of life from qualitative data

Predictive Analytics

Predictive models for disease progression and treatment response are essential for precision medicine approaches[16]:

• Progression prediction: Models that forecast time to disease milestones based on baseline characteristics
• Response prediction: Algorithms that identify patients most likely to benefit from specific treatments
• Risk stratification: Tools that prioritize high-risk patients for intervention
• Resource planning: Forecasting healthcare utilization to enable proactive care management

Technology Platform

IQVIA's technology infrastructure provides the foundation for its analytics capabilities:

| Platform | Function | Application |
|----------|----------|-------------|
| Discover | Analytics workspace | Ad hoc analysis and visualization |
| Orchestrate | Clinical operations | Trial management and execution |
| Intelligence | Real-time dashboards | Performance monitoring |
| Patient Cloud | Data integration | Multi-source data harmonization |
| NOVA | Advanced analytics | ML model development and deployment |

Market Position

Competitors

IQVIA operates in a competitive landscape with several significant players:

| Competitor | Primary Strength | IQVIA Differentiation |
|------------|-----------------|----------------------|
| Optum | Integrated payer data | Broader pharma/biotech focus |
| Syneos Health | Full-service CRO | Superior data assets |
| Cegedim | European market presence | Global coverage |
| Real-Life Scientific | Academic partnerships | Scale and commercial orientation |
| Health Catalyst | Hospital system data | Life sciences focus |
| TriNetX | Academic research network | Enterprise analytics depth |

Strategic Focus Areas

IQVIA's strategic priorities reflect market opportunities and competitive positioning:

Financial Performance

| Metric | 2024 | 2023 | 2022 | Change 2023-24 |
|--------|------|------|------|----------------|
| Revenue | $7.4B | $6.9B | $6.4B | +7.2% |
| Adjusted EBITDA | $2.2B | $2.0B | $1.8B | +10% |
| Operating Margin | 18.5% | 17.8% | 17.1% | +0.7pp |
| RWE Revenue | $1.8B | $1.6B | $1.4B | +12.5% |

The growth in RWE revenue reflects increasing demand from pharmaceutical sponsors seeking to leverage real-world data for regulatory submissions, health technology assessment, and medical affairs applications.

Relevance to NeuroWiki

IQVIA's data and analytics capabilities align with NeuroWiki's mission to build a comprehensive mechanistic knowledge base for neurodegenerative diseases:

• Treatment patterns: Understanding how AD and PD patients are treated in routine clinical practice
• Clinical outcomes: Real-world evidence on treatment effectiveness and safety
• Healthcare utilization: Mapping the care pathways and resource consumption associated with neurodegenerative diseases
• Patient populations: Characterizing the demographic and clinical heterogeneity of patient populations
• Trial landscapes: Tracking the competitive landscape of ongoing clinical trials

See Also

• [AD Real-World Evidence Companies](/companies/ad-real-world-evidence-companies)
• [AD Pipeline Companies](/companies/ad-pipeline-companies)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Healthcare Data Analytics](/topics/healthcare-data-analytics)

External Links

• [IQVIA Website](https://www.iqvia.com)
• [Real-World Evidence Solutions](https://www.iqvia.com/solutions/research-and-analytics/real-world-evidence)
• [Alzheimer's Disease Solutions](https://www.iqvia.com/solutions-and-services/life-sciences/alzheimers-disease)

References